[from the 06/27/2016 edition of Breakthrough Tech Weekly]

I found two stocks in our portfolio that are likely to face some headwinds due to Brexit related issues, Amgen (AMGN) and Bio-rad (BIO), so I recommend their immediate sales.

Amgen is especially vulnerable, being a member of the Nasdaq 100 Index, the weakest index in the U.S. market at the moment.  To be sure, investors sell what they can during market meltdowns and Amgen is a liquid stock.  But beyond that fact, Amgen is facing a great deal of uncertainty after the Brexit, as investors will have to start pricing in changes in any existing deals that the company is currently involved in as well as potential disruptions in future drug approvals and in the company’s ability to continue with ongoing clinical trials.

Bio-rad is vulnerable because it is a specialist in the diagnostics field. And although it offers very specific laboratory testing equipment, testing products and reagents to hospitals and other health care facilities the Brexit could interrupt the flow of business for Bio-rad as facilities may cut back on upgrades or cancel orders for back up equipment due to budgetary uncertainties. 

Sell Amgen and Bio-rad.